The clinical application of rituximabin in treatment of refractory nephrotic syndrome in children

The clinical application of rituximab in treatment of refractory nephrotic syndrome in children

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-10001125

Enrollment

Unknown

Registered

2010-12-04

Start date

2011-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory nephrotic syndrome in children

Interventions

1:rituximab 375mg/m2

Eligibility

Sex/Gender

All

Age

3 Years to 15 Years

Inclusion criteria

Inclusion criteria: Children with refractory nephrotic syndrome and unsensitive to other medicine

Exclusion criteria

Exclusion criteria: Patients who are allergic to rituximab or mouse protein

Design outcomes

Primary

Measure	Time frame
CD8;CD20;CD4;CD19;CD3;	—

Secondary

Measure	Time frame
immunoglobulin;B lymphocyte count;liver and kidney function;blood routine test;renal pathology;	—

Countries

China

Contacts

Public ContactZhengkun Xia

njxzk@126.com+86 025 80861386

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026